Eli Lilly LLY
-
BMO Capital initiates coverage on a few of the big drug companies today: Eli Lilly ([[LLY]] -0.1%) and Merck ([[MRK]] -0.4%) are initiated with a Market Perform, and Bristol-Myers ([[BMY]] +0.1%) is ...
BMO Capital initiates coverage on a few of the big drug companies today: Eli Lilly ( LLY -0.1% ) and Merck ( MRK -0.4% ) are initiated with a Market Perform, and Bristol-Myers ( BMY +0.1% ) is started with an Outperform . Post your comment!
-
Eli Lilly Could Sink On Drug Collusion In India
By Stock Croc : Recent discoveries have placed Eli Lilly ( LLY ) in the spotlight for colluding with India's drug regulators. Eli Lilly , along with other Big Pharma names such as GlaxoSmithKline …
-
Eli Lilly & Co. Undervalued By Up To 30%
By Vytautas Drumelis : Eli Lilly & Co. ( LLY ) operates in the Drug Manufacturers industry. I think this stock undervalued by up to 30% or even more. Discounted …
-
Eli Lilly Is Ready To Soar On Strong Pipeline In 2013
By Mel Daris : Patients' lives are changed when psychiatrists prescribe certain antipsychotic medicines. Antipsychotic medicines usually have a number of side effects that are very unpleasant. Typical antipsychotics, which were the first generation of this class, changed the way we look at mental
-
New Morningstar Analyst Report - WuXi PharmaTech (Cayman), Inc.
… quality, service, and protection of customer intellectual property. The company has received recognition from Merck, Eli Lilly , and Pfizer, among others.WuXi receives preferential tax treatment and financial incentives from the Chinese government …
-
New Morningstar Analyst Report - MannKind Corporation
… smokers prompted diabetes experts such as Novo Nordisk and Eli Lilly to discontinue their inhaled insulin products.Afrezza ..... causing diabetes experts such as Novo Nordisk NVO and Eli Lilly LLY to withdraw their own inhaled insulin products from …
-
4 Big Pharma Stocks To Nab In A Pullback
… Singulair sales. Merck, of course, is not the only big pharma player to face patent expirations on its blockbuster drugs. Eli Lilly ( LLY ) faced similar challenges to revenue growth when its Complete Story »
-
China Biotech In Review: Surgical Instrument Acquisition Takes Mindray Into New Territory
… set to attend the conference, including Aosaikang, AstraZeneca, Bayer HealthCare, BeiGene, Boehringer Ingelheim, Eli Lilly , Fosun Pharma, Furen Pharma, Hanmi Pharmaceutical, Hengrui Pharmaceuticals, Hua Medicine, Janssen/J&J, Life …
-
Eli Lilly Looks Like A Short
By Gene Andrews : Observe, Orientate, Decide and then Act If one is to know truly one must see truly. The power and importance of observation cannot be overstated. The stock market is not an environment that allows the application of the scientific method. We cannot subject a control group to a ...
-
New Morningstar Analyst Report - Amgen
… drugs such as Novartis' Reclast and cheaper generic bisphosphonates; Vectibix competes with Roche's RHHBY Avastin and Eli Lilly LLY and Bristol-Myers Squibb's BMY Erbitux. If Amgen's late-stage pipeline disappoints, the company could be …